Omada Health (NASDAQ:OMDA) Raised to Buy at Wall Street Zen

Omada Health (NASDAQ:OMDA) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts also recently issued research reports about the company. Barclays raised their price target on Omada Health from $20.00 to $25.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Weiss Ratings lowered Omada Health from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, July 13th. Citigroup reissued an “outperform” rating on shares of Omada Health in a report on Monday, July 20th. BMO Capital Markets restated an “outperform” rating and issued a $24.00 target price on shares of Omada Health in a research report on Friday. Finally, BTIG Research assumed coverage on Omada Health in a research note on Friday, July 17th. They issued a “buy” rating and a $30.00 target price for the company. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $25.25.

Omada Health Price Performance

Shares of NASDAQ:OMDA opened at $23.67 on Friday. The company’s fifty day moving average price is $20.36 and its 200-day moving average price is $16.20. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of 473.40 and a beta of 1.73. Omada Health has a one year low of $10.28 and a one year high of $26.92.

Omada Health (NASDAQ:OMDA) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.10. Omada Health had a net margin of 1.39% and a return on equity of 2.67%. The company had revenue of $87.83 million during the quarter, compared to the consensus estimate of $80.93 million. As a group, equities research analysts expect that Omada Health will post -0.01 EPS for the current year.

Insider Buying and Selling at Omada Health

In other news, CFO Steven L. Cook sold 33,000 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $19.89, for a total transaction of $656,370.00. Following the completion of the sale, the chief financial officer directly owned 133,359 shares in the company, valued at approximately $2,652,510.51. This represents a 19.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Craig Gracey sold 6,894 shares of the firm’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $17.42, for a total value of $120,093.48. Following the completion of the sale, the chief accounting officer directly owned 9,191 shares in the company, valued at $160,107.22. The trade was a 42.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 206,406 shares of company stock worth $4,191,483. 6.38% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Omada Health

Institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC bought a new stake in shares of Omada Health in the 2nd quarter worth approximately $637,000. Walleye Capital LLC bought a new position in shares of Omada Health during the second quarter valued at approximately $458,000. Ilex Capital Partners UK LLP purchased a new stake in Omada Health in the second quarter worth $201,000. Soros Fund Management LLC purchased a new stake in Omada Health in the second quarter worth $640,000. Finally, Raymond James Financial Inc. bought a new stake in Omada Health in the second quarter valued at $32,000.

Trending Headlines about Omada Health

Here are the key news stories impacting Omada Health this week:

• Positive Sentiment: Second-quarter results exceeded expectations: Omada reported revenue of approximately $87.8 million, above the $80.9 million consensus estimate. Adjusted earnings per share also surpassed forecasts, with reports citing approximately $0.08 to $0.15 per share versus expectations ranging from a loss of $0.02 to $0.05. Results improved from a year-earlier loss. Omada Health quarterly earnings report
• Positive Sentiment: Growth remained strong: Second-quarter revenue rose 43% year over year, while total members increased 45%. Omada also achieved a record quarterly gross margin, supporting the case that operating leverage and scale are improving. Omada Health second-quarter results
• Positive Sentiment: 2026 revenue guidance was raised or reaffirmed above consensus: Omada projected full-year revenue of $334 million to $340 million, exceeding the approximately $327.2 million analyst estimate. The outlook signals continued demand for its virtual chronic-care platform. Omada Health revenue outlook
• Neutral Sentiment: Leadership transition announced: Co-founder and CEO Sean Duffy will become executive chair on January 1, 2027, while President Wei-Li Shao is scheduled to become CEO. The planned, internal succession may provide continuity, although investors could monitor execution under the new leadership. Omada Health CEO transition
• Negative Sentiment: CEO stock sale adds a modest overhang: Duffy sold 12,944 shares for approximately $264,000, reducing his direct position by 3.05%. The sale occurred before the earnings release and may be routine, but insider selling can temper sentiment.

Omada Health Company Profile

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.

In addition to its core disease-management offerings, Omada Health has expanded its services to include mental health support and digital therapeutics for weight management.